import Navigation from "@/components/Navigation";
import { Card, CardContent, CardHeader, CardTitle } from "@/components/ui/card";
import { Badge } from "@/components/ui/badge";
import { Button } from "@/components/ui/button";
import { usePageTitle } from "@/hooks/usePageTitle";
import { Link } from "wouter";
import { Shield, AlertTriangle, FileText, Scale, Building2, BookOpen, ClipboardCheck } from "lucide-react";

export default function BlogDefensiblePeptidePractice() {
  usePageTitle("Building a Defensible Peptide Practice: The 5-Point Risk Management Framework for 2026 | PepEdHub");

  return (
    <div className="min-h-screen bg-gray-50">
      <Navigation />
      <div className="max-w-4xl mx-auto px-4 py-12">
        {/* Breadcrumb */}
        <nav className="mb-8">
          <ol className="flex items-center space-x-2 text-sm text-gray-500">
            <li><Link href="/" className="hover:text-blue-600">Home</Link></li>
            <li>/</li>
            <li><Link href="/blog" className="hover:text-blue-600">Blog</Link></li>
            <li>/</li>
            <li className="text-gray-900">Defensible Peptide Practice</li>
          </ol>
        </nav>

        {/* Header */}
        <div className="mb-10">
          <div className="flex flex-wrap gap-2 mb-4">
            <Badge className="bg-blue-100 text-blue-800">Risk Management</Badge>
            <Badge className="bg-purple-100 text-purple-800">Practice Building</Badge>
            <Badge className="bg-red-100 text-red-800">Regulatory Compliance</Badge>
          </div>
          <h1 className="text-4xl font-bold text-gray-900 mb-4">
            Building a Defensible Peptide Practice: The 5-Point Risk Management Framework for 2026
          </h1>
          <p className="text-xl text-gray-600 mb-4">
            A structured approach to offering peptide therapy while minimizing regulatory, legal, and malpractice exposure in an evolving enforcement landscape.
          </p>
          <div className="flex items-center gap-4 text-sm text-gray-500">
            <span>PepEdHub Clinical Team</span>
            <span>|</span>
            <span>February 2026</span>
            <span>|</span>
            <span>12 min read</span>
          </div>
        </div>

        {/* Key Takeaways */}
        <Card className="mb-10 border-blue-200 bg-blue-50">
          <CardHeader>
            <CardTitle className="flex items-center gap-2 text-blue-900">
              <Shield className="w-5 h-5" />
              Key Takeaways
            </CardTitle>
          </CardHeader>
          <CardContent className="space-y-2 text-blue-800">
            <p>• The federal posture around peptides is moving toward more explicit restriction, not less</p>
            <p>• "Popular" does not equal "approved" or "proven" — this distinction is your first line of defense</p>
            <p>• A structured risk-management framework protects you better than asking "how do I prescribe BPC-157?"</p>
            <p>• The 5-point framework: Legal Anchoring → Risk Stratification → Investigational Framing → Professional Protection → Education Systems</p>
            <p>• Physicians who document, consent properly, and avoid commercialization optics are far less likely to face enforcement</p>
          </CardContent>
        </Card>

        {/* Introduction */}
        <div className="prose max-w-none mb-10">
          <h2 className="text-2xl font-bold text-gray-900 mb-4">The Landscape Has Changed</h2>
          <p className="text-gray-700 mb-4">
            Peptide therapy demand is exploding. Patients arrive at your practice having already researched BPC-157, TB-500, and GHK-Cu online. Thousands of peptide companies operate on the internet. Compounding pharmacies — both compliant and questionable — are filling orders daily. And physicians across the country are incorporating peptides into their practices at an unprecedented rate.
          </p>
          <p className="text-gray-700 mb-4">
            But the regulatory environment is not standing still. The FDA has placed multiple popular peptides into Category 2 status on the 503A bulks list, effectively interpreting this as "do not compound." Warning letters have been issued to compounders and clinics. The DoD, USADA, and WADA have all flagged BPC-157 as unapproved or prohibited. And state medical boards are beginning to scrutinize peptide practices more closely.
          </p>
          <p className="text-gray-700 mb-4">
            For a US physician in 2026 who wants to help patients and not become the test case, the question is not "how do I prescribe BPC-157?" but rather "how do I build a defensible practice framework?" This article presents a 5-point risk management framework designed to help practitioners navigate this gray zone with intention, documentation, and legal awareness.
          </p>
        </div>

        {/* Point 1 */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <Scale className="w-6 h-6 text-blue-600" />
              <span className="text-2xl">1. Anchor in the Actual Legal Landscape</span>
            </CardTitle>
          </CardHeader>
          <CardContent className="space-y-4">
            <p className="text-gray-700">
              The first step in building a defensible practice is understanding exactly where you stand legally. Many practitioners operate under assumptions that don't hold up to scrutiny.
            </p>

            <div className="bg-red-50 border border-red-200 rounded-lg p-4">
              <h4 className="font-bold text-red-900 mb-2 flex items-center gap-2">
                <AlertTriangle className="w-5 h-5" />
                Critical Legal Distinctions
              </h4>
              <ul className="space-y-3 text-red-800">
                <li><strong>BPC-157 is NOT "off-label"</strong> — It has zero FDA approvals for any indication. Using it is not off-label prescribing (which has decades of legal precedent protecting physicians); it is use of an unapproved new drug, which carries fundamentally different liability exposure.</li>
                <li><strong>Category 2 status</strong> — FDA has placed BPC-157, TB-500, TA1, CJC-1295, Ipamorelin, AOD-9604, Melanotan II, and GHK-Cu into Category 2 on the 503A bulks list. FDA interprets this as "do not compound this substance."</li>
                <li><strong>Compounded drugs are NOT FDA-approved</strong> — Even when sourced from a licensed 503A pharmacy, the resulting product has not undergone FDA review for safety, efficacy, or manufacturing quality.</li>
                <li><strong>Research-grade products</strong> — Products labeled "for research use only" or "not for human use" that are routed into patient care have been explicitly treated by FDA as misbranded drugs.</li>
              </ul>
            </div>

            <p className="text-gray-700">
              Understanding these distinctions is not about discouraging peptide use — it's about ensuring that your practice decisions are grounded in legal reality rather than industry marketing. A physician who knows the regulatory landscape can make informed decisions about risk; one who doesn't is flying blind.
            </p>

            <div className="bg-gray-50 border rounded-lg p-4">
              <h4 className="font-semibold text-gray-900 mb-2">Key References</h4>
              <ul className="text-sm text-gray-600 space-y-1">
                <li>• <a href="https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-federal-food-drug-and-cosmetic-act" className="text-blue-600 hover:underline" target="_blank" rel="noopener noreferrer">FDA 503A Bulks List</a></li>
                <li>• <a href="https://frierlevitt.com/blog/regulatory-status-of-peptide-compounding-in-2025/" className="text-blue-600 hover:underline" target="_blank" rel="noopener noreferrer">Frier Levitt: Regulatory Status of Peptide Compounding</a></li>
                <li>• <a href="https://www.statnews.com/2024/03/19/peptides-bpc-157-fda-crackdown/" className="text-blue-600 hover:underline" target="_blank" rel="noopener noreferrer">STAT News: FDA Peptide Enforcement</a></li>
              </ul>
            </div>
          </CardContent>
        </Card>

        {/* Point 2 */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <ClipboardCheck className="w-6 h-6 text-green-600" />
              <span className="text-2xl">2. Separate What You CAN Do from What You Probably Should Not</span>
            </CardTitle>
          </CardHeader>
          <CardContent className="space-y-4">
            <p className="text-gray-700">
              Not all peptide therapy carries the same risk. A clear-eyed assessment of the risk spectrum helps you make better decisions about which peptides to incorporate and under what conditions.
            </p>

            <div className="grid md:grid-cols-2 gap-4">
              <div className="bg-green-50 border border-green-200 rounded-lg p-4">
                <h4 className="font-bold text-green-900 mb-3">Relatively Safer Territory</h4>
                <ul className="space-y-2 text-green-800 text-sm">
                  <li>• <strong>FDA-approved peptide drugs</strong> — GLP-1 agonists (semaglutide, tirzepatide), insulin, HGH, certain gonadotropins — used within or, when supportable, off-label for appropriate indications with documentation of evidence and rationale</li>
                  <li>• <strong>Category 1 peptides</strong> — Substances clearly within 503A/503B allowance (USP monograph, GRAS status) sourced from compliant pharmacies adhering to USP 795/797</li>
                  <li>• <strong>Risk-balanced protocols</strong> — Where the peptide is an adjunct to standard of care rather than a replacement, with clear documentation of clinical rationale</li>
                </ul>
              </div>

              <div className="bg-red-50 border border-red-200 rounded-lg p-4">
                <h4 className="font-bold text-red-900 mb-3">High-Risk Territory</h4>
                <ul className="space-y-2 text-red-800 text-sm">
                  <li>• <strong>Category 2 peptides via 503A</strong> — Prescribing BPC-157 or other Category 2 peptides through 503A compounders for general wellness, sports, or "optimization" use</li>
                  <li>• <strong>Research-use-only sourcing</strong> — Using overseas suppliers or "research-use only" labeled products and routing them into patient care</li>
                  <li>• <strong>Branded peptide programs</strong> — Marketing peptides as clinic "packages" or branded programs available to anyone willing to pay</li>
                </ul>
              </div>
            </div>

            <p className="text-gray-700">
              If you choose to work in the high-risk territory at all, it should be under very limited, defensible conditions — not as routine practice. The next section explains how to create those conditions.
            </p>
          </CardContent>
        </Card>

        {/* Point 3 */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <BookOpen className="w-6 h-6 text-purple-600" />
              <span className="text-2xl">3. If Using Unapproved Peptides, Make It Look Like Formal Investigation</span>
            </CardTitle>
          </CardHeader>
          <CardContent className="space-y-4">
            <p className="text-gray-700">
              For unapproved agents like BPC-157, the most defensible posture is to frame your use as systematic investigation rather than casual prescribing. This means building quasi-clinical frameworks around what you do.
            </p>

            <div className="space-y-4">
              <div className="border-l-4 border-purple-500 pl-4">
                <h4 className="font-bold text-gray-900 mb-2">Narrow, High-Need Indications</h4>
                <p className="text-gray-700 text-sm">
                  Restrict to patients with serious conditions where conventional and evidence-based options are exhausted or poorly tolerated. A refractory tendinopathy patient in whom surgery and PRP have failed, entering a registry protocol with BPC-157, with defined outcomes, time-limited trial, and proper consent, is far easier to defend than "performance peptide" packages available to anyone with a credit card.
                </p>
              </div>

              <div className="border-l-4 border-purple-500 pl-4">
                <h4 className="font-bold text-gray-900 mb-2">Robust Consent Language</h4>
                <p className="text-gray-700 text-sm">
                  Your consent should clearly state: unapproved status (not "off-label"), lack of FDA evaluation, limited human data (fewer than 30 human subjects for BPC-157), theoretical immunogenicity and impurity risks, batch variability, absence of sterility guarantee, and absence of guarantee of benefit. See our <Link href="/resources/consent-forms" className="text-blue-600 hover:underline">state-specific consent form templates</Link>.
                </p>
              </div>

              <div className="border-l-4 border-purple-500 pl-4">
                <h4 className="font-bold text-gray-900 mb-2">IRB or Ethics/Legal Review</h4>
                <p className="text-gray-700 text-sm">
                  If feasible, run true prospective case series or registries with IRB oversight, even if single-site. This frames your use as systematic investigation rather than casual prescribing. Our <Link href="/resources/consent-forms/form-7" className="text-blue-600 hover:underline">Multi-Peptide Protocol with Registry consent form</Link> is designed for exactly this purpose.
                </p>
              </div>

              <div className="border-l-4 border-purple-500 pl-4">
                <h4 className="font-bold text-gray-900 mb-2">Meticulous Documentation</h4>
                <p className="text-gray-700 text-sm">
                  Document: literature reviewed, alternative options discussed, why this patient is a candidate, dosing rationale, monitoring plan, adverse-event surveillance, and periodic re-evaluation to discontinue if no objective benefit. This creates a paper trail that demonstrates good-faith clinical reasoning.
                </p>
              </div>

              <div className="border-l-4 border-purple-500 pl-4">
                <h4 className="font-bold text-gray-900 mb-2">Avoid Commercialization Optics</h4>
                <p className="text-gray-700 text-sm">
                  Do not market BPC-157 or similar as a branded clinic "program." Avoid online claims of efficacy. Don't sell directly like a supplement. These are patterns that have drawn FDA and state medical board attention. Your peptide use should look like careful clinical practice, not a retail operation.
                </p>
              </div>
            </div>

            <div className="bg-purple-50 border border-purple-200 rounded-lg p-4 mt-4">
              <h4 className="font-semibold text-purple-900 mb-2">The Defensibility Test</h4>
              <p className="text-purple-800 text-sm">
                Ask yourself: "If a state medical board investigator reviewed my chart for this patient, would they see a careful clinician who exhausted conventional options and documented a thoughtful rationale for an investigational approach? Or would they see a practitioner dispensing unapproved drugs for profit?" The answer to that question determines your defensibility.
              </p>
            </div>
          </CardContent>
        </Card>

        {/* Point 4 */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <Building2 className="w-6 h-6 text-orange-600" />
              <span className="text-2xl">4. Protect Yourself via Sourcing, Policies, and Professional Coverage</span>
            </CardTitle>
          </CardHeader>
          <CardContent className="space-y-4">
            <p className="text-gray-700">
              Beyond clinical documentation, structural protections create additional layers of defense.
            </p>

            <div className="space-y-4">
              <div className="bg-orange-50 border border-orange-200 rounded-lg p-4">
                <h4 className="font-bold text-orange-900 mb-2">Pharmacy Sourcing</h4>
                <p className="text-orange-800 text-sm">
                  Work only with pharmacies that can demonstrate compliance with USP 797/795 standards, have clean state and FDA inspection histories, and are not on the FDA radar for insanitary conditions or misbranding. Request certificates of analysis (COAs) and verify them. If using research-grade products, understand that this carries additional risk and must be disclosed to patients.
                </p>
              </div>

              <div className="bg-orange-50 border border-orange-200 rounded-lg p-4">
                <h4 className="font-bold text-orange-900 mb-2">Written Clinic Policy</h4>
                <p className="text-orange-800 text-sm">
                  Maintain a written clinic policy on peptide prescribing that references FDA and state guidance, explains which classes of peptides you will use (FDA-approved, Category 1, etc.), and explicitly addresses your approach to Category 2 substances. This document shows regulators and insurers that you are acting in good faith to align with evolving regulation.
                </p>
              </div>

              <div className="bg-orange-50 border border-orange-200 rounded-lg p-4">
                <h4 className="font-bold text-orange-900 mb-2">Malpractice Carrier Communication</h4>
                <p className="text-orange-800 text-sm">
                  Discuss your peptide practice with your malpractice carrier and, if possible, a healthcare regulatory attorney familiar with your state's law and recent peptide enforcement actions. This does two things: it shows you're acting in good faith, and it avoids surprising your carrier with a claim they think you created by practicing outside accepted boundaries. See our <Link href="/blog/malpractice-carrier-peptide-practice" className="text-blue-600 hover:underline">detailed guide on malpractice carrier communication</Link>.
                </p>
              </div>
            </div>
          </CardContent>
        </Card>

        {/* Point 5 */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <FileText className="w-6 h-6 text-teal-600" />
              <span className="text-2xl">5. Build Around Education and Systems, Not Just the Peptide</span>
            </CardTitle>
          </CardHeader>
          <CardContent className="space-y-4">
            <p className="text-gray-700">
              The most defensible peptide practitioners are those who position themselves as careful, science-driven early adopters rather than rogue prescribers. Your comparative advantage is in:
            </p>

            <ul className="space-y-3 text-gray-700">
              <li className="flex items-start gap-2">
                <span className="text-teal-600 font-bold mt-1">→</span>
                <span><strong>Protocolized, multimodal regenerative plans</strong> where peptides are a small, clearly justified piece of a comprehensive treatment approach — not the centerpiece of your marketing.</span>
              </li>
              <li className="flex items-start gap-2">
                <span className="text-teal-600 font-bold mt-1">→</span>
                <span><strong>Patient and clinician education</strong> on what is known and unknown about each compound, emphasizing that "popular" does not equal "approved" or "proven." Informed patients are your best defense.</span>
              </li>
              <li className="flex items-start gap-2">
                <span className="text-teal-600 font-bold mt-1">→</span>
                <span><strong>Contributing structured data</strong> (N-of-1 studies, case series, registry data) that could eventually support more formal pathways, including PCAC review and potential Category 1 status for some compounds.</span>
              </li>
            </ul>

            <p className="text-gray-700">
              This approach positions your practice for long-term sustainability regardless of how the regulatory landscape evolves. If peptides gain broader approval, you'll have the data and infrastructure to lead. If enforcement tightens, you'll have the documentation and frameworks to demonstrate good-faith clinical practice.
            </p>
          </CardContent>
        </Card>

        {/* Summary Framework */}
        <Card className="mb-10 border-2 border-blue-300">
          <CardHeader>
            <CardTitle className="text-2xl text-center">The 5-Point Framework at a Glance</CardTitle>
          </CardHeader>
          <CardContent>
            <div className="overflow-x-auto">
              <table className="w-full text-sm">
                <thead>
                  <tr className="bg-blue-50">
                    <th className="text-left p-3 font-bold">Point</th>
                    <th className="text-left p-3 font-bold">Action</th>
                    <th className="text-left p-3 font-bold">Key Deliverable</th>
                  </tr>
                </thead>
                <tbody>
                  <tr className="border-t">
                    <td className="p-3 font-semibold">1. Legal Anchoring</td>
                    <td className="p-3">Know the difference between approved, off-label, and unapproved</td>
                    <td className="p-3">Regulatory reference document for your practice</td>
                  </tr>
                  <tr className="border-t bg-gray-50">
                    <td className="p-3 font-semibold">2. Risk Stratification</td>
                    <td className="p-3">Categorize peptides by regulatory risk level</td>
                    <td className="p-3">Written policy on which peptides you will/won't use</td>
                  </tr>
                  <tr className="border-t">
                    <td className="p-3 font-semibold">3. Investigational Framing</td>
                    <td className="p-3">Treat unapproved peptide use as systematic investigation</td>
                    <td className="p-3">Consent forms, registry protocols, documentation templates</td>
                  </tr>
                  <tr className="border-t bg-gray-50">
                    <td className="p-3 font-semibold">4. Professional Protection</td>
                    <td className="p-3">Secure sourcing, policies, and insurance coverage</td>
                    <td className="p-3">Pharmacy verification, clinic policy, carrier notification</td>
                  </tr>
                  <tr className="border-t">
                    <td className="p-3 font-semibold">5. Education Systems</td>
                    <td className="p-3">Build around education, not just the molecule</td>
                    <td className="p-3">Patient education materials, data collection infrastructure</td>
                  </tr>
                </tbody>
              </table>
            </div>
          </CardContent>
        </Card>

        {/* CTA */}
        <Card className="mb-10 bg-gradient-to-r from-blue-600 to-purple-600 text-white">
          <CardContent className="p-8 text-center">
            <h3 className="text-2xl font-bold mb-4">Start Building Your Defensible Practice Today</h3>
            <p className="mb-6 text-blue-100">
              Download our state-specific consent form templates, designed for research-grade peptide therapy with all the regulatory language you need.
            </p>
            <Link href="/resources/consent-forms">
              <Button className="bg-white text-blue-600 hover:bg-blue-50 font-bold px-8 py-3">
                View Consent Form Templates →
              </Button>
            </Link>
          </CardContent>
        </Card>

        {/* Related Articles */}
        <div className="mb-10">
          <h3 className="text-xl font-bold text-gray-900 mb-4">Related Articles</h3>
          <div className="grid md:grid-cols-2 gap-4">
            <Link href="/blog/off-label-vs-unapproved-bpc-157">
              <Card className="hover:shadow-lg transition-shadow cursor-pointer h-full">
                <CardContent className="p-4">
                  <Badge className="bg-red-100 text-red-800 mb-2">Regulatory</Badge>
                  <h4 className="font-semibold text-gray-900">Off-Label vs. Unapproved: Why BPC-157 Is NOT an Off-Label Prescription</h4>
                </CardContent>
              </Card>
            </Link>
            <Link href="/blog/fda-category-1-vs-category-2-peptides">
              <Card className="hover:shadow-lg transition-shadow cursor-pointer h-full">
                <CardContent className="p-4">
                  <Badge className="bg-blue-100 text-blue-800 mb-2">FDA Guidance</Badge>
                  <h4 className="font-semibold text-gray-900">FDA Category 1 vs Category 2: Understanding the 503A Bulks List</h4>
                </CardContent>
              </Card>
            </Link>
            <Link href="/blog/malpractice-carrier-peptide-practice">
              <Card className="hover:shadow-lg transition-shadow cursor-pointer h-full">
                <CardContent className="p-4">
                  <Badge className="bg-orange-100 text-orange-800 mb-2">Risk Management</Badge>
                  <h4 className="font-semibold text-gray-900">Why Your Malpractice Carrier Needs to Know About Your Peptide Practice</h4>
                </CardContent>
              </Card>
            </Link>
            <Link href="/resources/consent-forms">
              <Card className="hover:shadow-lg transition-shadow cursor-pointer h-full">
                <CardContent className="p-4">
                  <Badge className="bg-green-100 text-green-800 mb-2">Resources</Badge>
                  <h4 className="font-semibold text-gray-900">Downloadable Consent Form Templates for Peptide Therapy</h4>
                </CardContent>
              </Card>
            </Link>
          </div>
        </div>

        {/* Disclaimer */}
        <div className="bg-yellow-50 border border-yellow-200 rounded-lg p-4 text-sm text-yellow-800">
          <p className="font-semibold mb-1">Disclaimer</p>
          <p>
            For informational purposes only. Not a substitute for professional medical advice. Use under practitioner supervision. This article does not constitute legal advice. Practitioners should consult with a healthcare regulatory attorney licensed in their state for specific legal guidance regarding peptide therapy practices.
          </p>
        </div>
      </div>
    </div>
  );
}
